17/06/2025 18:41
|
Medical, Health & Aged Care
BARCELONA, Spain--BUSINESS WIRE--
Ferrer, a B Corp-certified international pharmaceutical company, has announced that FNP-223, a novel therapy in-licensed from Asceneuron and aimed at slowing the...